Thr46
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr46  -  4E-BP1 (human)

Site Information
GGtLFsttPGGtRII   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447496
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 165 , 167 , 168 ) , electrophoretic mobility shift ( 151 , 164 , 166 ) , immunoassay ( 50 ) , immunoprecipitation ( 8 , 9 , 14 , 28 , 38 ) , mass spectrometry ( 2 , 9 , 11 , 18 , 19 , 25 , 26 , 27 , 29 , 30 , 31 , 40 , 41 , 42 , 43 , 47 , 49 , 52 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 100 , 103 , 104 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 116 , 117 , 119 , 120 , 122 , 123 , 125 , 126 , 129 , 130 , 131 , 133 , 134 , 143 , 144 , 145 , 146 , 149 , 152 , 153 , 154 , 155 , 156 , 157 , 158 , 159 , 160 , 165 , 167 ) , mutation of modification site ( 3 , 8 , 9 , 14 , 19 , 164 , 165 , 166 , 167 , 168 ) , peptide sequencing ( 15 ) , phospho-antibody ( 1 , 3 , 4 , 5 , 7 , 8 , 9 , 12 , 13 , 14 , 16 , 17 , 19 , 20 , 23 , 28 , 38 , 44 , 45 , 46 , 50 , 101 , 105 , 115 , 118 , 121 , 124 , 127 , 128 , 135 , 136 , 137 , 139 , 140 , 141 , 142 , 147 , 148 , 150 , 151 , 161 , 162 , 163 , 164 , 165 , 166 , 167 ) , phosphopeptide mapping ( 165 , 167 ) , western blotting ( 1 , 3 , 4 , 5 , 7 , 8 , 9 , 12 , 13 , 14 , 15 , 16 , 17 , 19 , 23 , 28 , 38 , 44 , 46 , 101 , 105 , 115 , 118 , 121 , 124 , 127 , 128 , 135 , 136 , 137 , 139 , 140 , 141 , 142 , 147 , 150 , 161 , 162 , 163 , 164 , 165 )
Disease tissue studied:
bone cancer ( 115 , 163 ) , brain cancer ( 5 , 115 , 125 ) , glioblastoma ( 5 , 115 , 125 ) , glioma ( 5 , 115 , 125 ) , breast cancer ( 12 , 18 , 19 , 26 , 115 , 147 ) , breast cancer, triple negative ( 19 ) , colorectal cancer ( 20 , 127 ) , colorectal carcinoma ( 20 , 127 ) , gastric cancer ( 30 , 31 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 73 , 76 , 77 , 78 , 80 , 81 , 82 , 86 , 87 , 91 , 92 , 95 , 97 , 100 , 103 , 104 , 106 , 107 , 117 ) , gastric carcinoma ( 30 , 31 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 73 , 76 , 77 , 78 , 80 , 81 , 82 , 86 , 87 , 91 , 92 , 95 , 97 , 100 , 103 , 104 , 106 , 107 , 117 ) , kidney cancer ( 4 ) , leukemia ( 114 , 131 , 140 , 143 , 144 , 147 ) , acute myelogenous leukemia ( 147 ) , chronic myelogenous leukemia ( 114 , 131 , 140 , 143 , 144 ) , lung cancer ( 1 , 13 , 43 , 69 , 70 , 71 , 72 , 74 , 75 , 79 , 83 , 84 , 85 , 89 , 90 , 93 , 94 , 96 , 98 , 108 , 113 , 115 , 127 , 142 ) , non-small cell lung cancer ( 1 , 13 , 69 , 70 , 71 , 72 , 74 , 75 , 79 , 83 , 84 , 85 , 89 , 90 , 93 , 94 , 96 , 98 , 108 , 113 , 127 , 142 ) , non-small cell lung adenocarcinoma ( 1 , 13 , 43 , 71 , 74 , 75 , 79 , 84 , 89 , 90 , 93 , 94 , 96 , 98 , 108 , 113 ) , non-small cell large cell lung carcinoma ( 1 , 13 ) , non-small cell squamous cell lung carcinoma ( 71 , 74 , 75 , 79 , 84 , 108 , 113 , 127 ) , lymphoma ( 16 ) , B cell lymphoma ( 16 ) , non-Hodgkin's lymphoma ( 16 ) , mantle cell lymphoma ( 16 ) , neuroblastoma ( 38 ) , ovarian cancer ( 45 , 46 ) , ovarian epithelial carcinoma ( 45 ) , prostate cancer ( 28 , 116 ) , psoriasis ( 118 )
Relevant cell line - cell type - tissue:
'muscle, skeletal' ( 124 , 128 , 141 ) , 'muscle, smooth' ( 137 ) , 1-LN (prostate cell) ( 28 ) , 293 (epithelial) ( 3 , 9 , 23 , 101 , 105 , 115 , 120 , 121 , 139 , 150 , 161 , 162 , 164 , 165 , 166 , 168 ) , 293 (epithelial) [4E-BP1 (human)] ( 167 ) , 293E (epithelial) ( 40 , 163 ) , 293T (epithelial) ( 8 , 11 , 14 , 139 , 167 ) , 3T3 (fibroblast) ( 139 ) , A427 (pulmonary) ( 1 ) , A549 (pulmonary) ( 1 , 13 , 115 , 127 ) , ACHN (renal) ( 4 ) , BV-173 (myeloid) ( 140 ) , DU 145 (prostate cell) ( 28 ) , FU-OV-1 (ovarian) ( 46 ) , HAEC (endothelial) ( 135 ) , HCC1806 (breast cell) ( 19 ) , HCT116 (intestinal) ( 127 ) , HCT15 (intestinal) ( 20 ) , HeLa (cervical) ( 2 , 3 , 8 , 14 , 44 , 47 , 49 , 52 , 109 , 110 , 111 , 112 , 123 , 129 , 133 , 139 ) , HMLER ('stem, breast cancer') ( 18 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 18 ) , HUES-7 ('stem, embryonic') ( 119 ) , JEKO-1 (B lymphocyte) ( 16 ) , Jurkat (T lymphocyte) ( 41 , 42 , 126 , 134 , 149 , 152 , 153 , 154 , 155 , 156 , 157 , 158 , 159 , 160 ) , K562 (erythroid) ( 25 , 114 , 130 , 131 , 140 , 143 , 144 , 145 , 146 ) , KATO III (gastric) ( 117 ) , L6 (myoblast) ( 9 ) , LCL (lymphoblastoid) ( 50 ) , LN229 (glial) ( 5 ) , LNCaP (prostate cell) ( 116 ) , lung ( 7 ) , MCF-7 (breast cell) ( 115 , 147 ) , MDA-MB-231 (breast cell) ( 12 ) , MEF (fibroblast) ( 44 , 139 ) , mesenchymal ( 7 ) , MKN-45 (gastric) ( 27 , 30 , 31 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 73 , 76 , 77 , 78 , 80 , 81 , 82 , 86 , 87 , 91 , 92 , 95 , 97 , 100 , 103 , 104 , 106 , 107 ) , NB-4 (myeloid) ( 147 , 148 ) , NCI-H1299 (pulmonary) ( 127 ) , NCI-H1650 (pulmonary) ( 127 ) , NCI-H1703 (squamous) ( 27 , 71 , 74 , 75 , 79 , 84 , 108 , 113 , 127 ) , NCI-H1792 (pulmonary) ( 142 ) , NCI-H1838 (pulmonary) ( 142 ) , NCI-H23 (pulmonary) ( 127 ) , NCI-H3255 (pulmonary) ( 27 , 69 , 70 , 72 , 83 , 85 ) , NCI-H441 (pulmonary) ( 89 , 90 , 93 , 94 , 96 , 98 ) , NCI-H460 (pulmonary) ( 1 , 13 , 127 ) , ovary ( 45 ) , OVCAR3 (ovarian) ( 46 ) , PC3 (prostate cell) ( 28 ) , SH-SY5Y (neural crest) ( 38 ) , SKBr3 (breast cell) ( 26 ) , skin ( 118 ) , SKOV-3 (ovarian) ( 46 ) , SW48 (intestinal) ( 20 ) , SW620 (intestinal) ( 20 ) , TOV21G (ovarian) ( 46 ) , U-1810 (pulmonary) ( 43 ) , U-1810 (pulmonary) [EFNB3 (human), knockdown] ( 43 ) , U266 (plasma cell) ( 151 ) , U2OS (bone cell) ( 115 ) , U2OS (bone cell) [GR (human)] ( 163 ) , U87MG (glial) ( 115 , 125 ) , WM115 (melanocyte) ( 122 ) , Z138 (B lymphocyte) ( 16 )

Upstream Regulation
Regulatory protein:
4E-BP1 (human) ( 132 ) , FAK (human) ( 139 ) , GSK3A (human) ( 19 ) , LKB1 (human) ( 127 ) , LRRK2 (human) ( 38 ) , mTOR (human) ( 135 ) , NOX4 (human) ( 137 ) , PKM (human) ( 8 ) , PRAS40 iso3 (human) ( 132 ) , Raptor (human) ( 7 ) , RHEB (human) ( 7 ) , SLC1A5 (human) ( 136 ) , TSC2 (human) ( 7 )
Putative in vivo kinases:
GSK3B (human) ( 19 ) , mTOR (rat) ( 162 , 166 , 167 )
Kinases, in vitro:
ERK2 (human) ( 166 ) , GSK3B (human) ( 4 , 19 ) , mTOR (human) ( 53 , 99 , 121 , 138 , 166 , 168 ) , mTOR (mouse) ( 101 )
Treatments:
1-azakenpaullone ( 19 ) , 8-CPT-2Me-cAMP ( 28 ) , AG2037 ( 1 ) , amino_acids ( 132 , 166 ) , anti-HLA ( 135 ) , AR-A014418 ( 4 , 19 ) , As2O3 ( 140 ) , AZD8055 ( 7 , 115 ) , bisindolylmaleimide ( 164 ) , dactolisib ( 15 ) , exercise ( 124 , 141 ) , fibronectin ( 142 ) , FMK-MEA ( 20 ) , gefitinib ( 27 ) , Go_6796 ( 7 ) , IFN-beta ( 151 ) , IFN-gamma ( 148 ) , imatinib ( 15 ) , insulin ( 128 , 132 , 150 , 163 , 164 , 166 ) , KPT-185 ( 16 ) , LY294002 ( 28 , 140 , 167 ) , mifepristone ( 136 ) , MK-2206 ( 7 ) , nilotinib ( 15 ) , OSI-027 ( 32 ) , PD0325901 ( 20 ) , PD184352 ( 164 ) , PD98059 ( 164 ) , phorbol_ester ( 132 , 164 ) , pimenta doica ( 12 ) , PP242 ( 20 ) , rapamycin ( 4 , 7 , 8 , 13 , 17 , 19 , 20 , 28 , 46 , 105 , 115 , 123 , 140 , 142 , 148 , 150 , 163 , 164 , 166 , 167 , 168 ) , SB216763 ( 13 ) , serum ( 165 , 167 ) , siRNA ( 127 ) , TGF-beta ( 137 ) , Torin1 ( 17 , 40 , 105 ) , U0126 ( 17 , 164 ) , wortmannin ( 7 )

Downstream Regulation
Effects of modification on 4E-BP1:
activity, inhibited ( 148 ) , molecular association, regulation ( 148 , 168 ) , phosphorylation ( 19 , 23 , 161 , 164 )
Effects of modification on biological processes:
autophagy, induced ( 14 ) , carcinogenesis, induced ( 20 ) , cell growth, induced ( 19 , 20 ) , translation, altered ( 124 )
Inhibit interaction with:
4E-BP1 (human) ( 168 ) , EIF4E (human) ( 148 , 168 )

Disease / Diagnostics Relevance
Relevant diseases:
ovarian epithelial carcinoma ( 45 ) , psoriasis ( 118 )

References 

1

Emmanuel N, et al. (2017) Purine Nucleotide Availability Regulates mTORC1 Activity through the Rheb GTPase. Cell Rep 19, 2665-2680
28658616   Curated Info

2

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

3

Velásquez C, et al. (2016) Mitotic protein kinase CDK1 phosphorylation of mRNA translation regulator 4E-BP1 Ser83 may contribute to cell transformation. Proc Natl Acad Sci U S A 113, 8466-71
27402756   Curated Info

4

Ito H, et al. (2016) GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition. BMC Cancer 16, 393
27387559   Curated Info

5

Iqbal A, et al. (2016) Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition. Oncotarget 7, 33192-201
27120806   Curated Info

6

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

7

Walker NM, et al. (2016) Mechanistic Target of Rapamycin Complex 1 (mTORC1) and mTORC2 as Key Signaling Intermediates in Mesenchymal Cell Activation. J Biol Chem 291, 6262-71
26755732   Curated Info

8

He CL, et al. (2016) Pyruvate Kinase M2 Activates mTORC1 by Phosphorylating AKT1S1. Sci Rep 6, 21524
26876154   Curated Info

9

Stretton C, et al. (2015) GSK3-mediated raptor phosphorylation supports amino-acid-dependent mTORC1-directed signalling. Biochem J 470, 207-21
26348909   Curated Info

10

Sekiyama N, et al. (2015) Molecular mechanism of the dual activity of 4EGI-1: Dissociating eIF4G from eIF4E but stabilizing the binding of unphosphorylated 4E-BP1. Proc Natl Acad Sci U S A 112, E4036-45
26170285   Curated Info

11

Franchin C, et al. (2015) Quantitative analysis of a phosphoproteome readily altered by the protein kinase CK2 inhibitor quinalizarin in HEK-293T cells. Biochim Biophys Acta 1854, 609-23
25278378   Curated Info

12

Zhang L, et al. (2015) Polyphenol-rich extract of Pimenta dioica berries (Allspice) kills breast cancer cells by autophagy and delays growth of triple negative breast cancer in athymic mice. Oncotarget 6, 16379-95
25945840   Curated Info

13

Koo J, et al. (2015) GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth. Oncotarget 6, 8974-87
25797247   Curated Info

14

Ber Y, et al. (2015) DAPK2 is a novel regulator of mTORC1 activity and autophagy. Cell Death Differ 22, 465-75
25361081   Curated Info

15

Yoda A, et al. (2015) Mutations in G protein β subunits promote transformation and kinase inhibitor resistance. Nat Med 21, 71-5
25485910   Curated Info

16

Tabe Y, et al. (2015) Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185. PLoS One 10, e0137210
26340096   Curated Info

17

Leontieva OV, Blagosklonny MV (2014) Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion. Oncotarget 5, 12715-27
25587030   Curated Info

18

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

19

Shin S, et al. (2014) Glycogen synthase kinase-3β positively regulates protein synthesis and cell proliferation through the regulation of translation initiation factor 4E-binding protein 1. Oncogene 33, 1690-9
23584478   Curated Info

20

Ducker GS, et al. (2014) Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene 33, 1590-600
23542178   Curated Info

21

Puustinen P, et al. (2014) CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation. J Cell Biol 204, 713-27
24590173   Curated Info

22

Ullal AV, et al. (2014) Cancer cell profiling by barcoding allows multiplexed protein analysis in fine-needle aspirates. Sci Transl Med 6, 219ra9
24431113   Curated Info

23

Shin S, Wolgamott L, Roux PP, Yoon SO (2014) Casein kinase 1ε promotes cell proliferation by regulating mRNA translation. Cancer Res 74, 201-11
24247720   Curated Info

24

Vendelbo MH, et al. (2014) Fasting Increases Human Skeletal Muscle Net Phenylalanine Release and This Is Associated with Decreased mTOR Signaling. PLoS One 9, e102031
25020061   Curated Info

25

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

26

Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57
22964224   Curated Info

27

Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201
22322096   Curated Info

28

Misra UK, Pizzo SV (2012) Upregulation of mTORC2 activation by the selective agonist of EPAC, 8-CPT-2Me-cAMP, in prostate cancer cells: assembly of a multiprotein signaling complex. J Cell Biochem 113, 1488-500
22173835   Curated Info

29

Rikova K (2012) CST Curation Set: 13732; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 1/treated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

30

Mulhern D (2012) CST Curation Set: 13402; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

31

Mulhern D (2012) CST Curation Set: 13405; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

32

Gupta M, et al. (2012) Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood 119, 476-87
22080480   Curated Info

33

Liu J, et al. (2011) PHLPP-mediated dephosphorylation of S6K1 inhibits protein translation and cell growth. Mol Cell Biol 31, 4917-27
21986499   Curated Info

34

Yellen P, et al. (2011) High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1. Cell Cycle 10, 3948-56
22071574   Curated Info

35

Rapley J, Oshiro N, Ortiz-Vega S, Avruch J (2011) The mechanism of insulin-stimulated 4E-BP protein binding to mammalian target of rapamycin (mTOR) complex 1 and its contribution to mTOR complex 1 signaling. J Biol Chem 286, 38043-53
21914810   Curated Info

36

Yuan J, et al. (2011) PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther 10, 2189-99
21750219   Curated Info

37

Clippinger AJ, Maguire TG, Alwine JC (2011) Human cytomegalovirus infection maintains mTOR activity and its perinuclear localization during amino acid deprivation. J Virol 85, 9369-76
21734039   Curated Info

38

Ohta E, Kawakami F, Kubo M, Obata F (2011) LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutations. FEBS Lett 585, 2165-70
21658387   Curated Info

39

Mazzoletti M, et al. (2011) Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates. Cancer Res 71, 4573-84
21602434   Curated Info

40

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

41

Guo A (2011) CST Curation Set: 11884; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

42

Guo A (2011) CST Curation Set: 11885; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

43

Ståhl S, et al. (2011) Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor. J Proteome Res 10, 2566-78
21413766   Curated Info

44

Saci A, Cantley LC, Carpenter CL (2011) Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size. Mol Cell 42, 50-61
21474067   Curated Info

45

No JH, et al. (2011) Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer. Gynecol Oncol 121, 8-12
21276607   Curated Info

46

Theurillat JP, et al. (2011) URI is an oncogene amplified in ovarian cancer cells and is required for their survival. Cancer Cell 19, 317-32
21397856   Curated Info

47

Guo A (2011) CST Curation Set: 11453; Year: 2011; Biosample/Treatment: cell line, HeLa/nocodazole &'||' pervanadate; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-PLK Binding Motif (ST*P) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (ST*P) Immunoaffinity Beads Cat#: 5756
Curated Info

48

Saiki S, et al. (2011) Caffeine induces apoptosis by enhancement of autophagy via PI3K/Akt/mTOR/p70S6K inhibition. Autophagy 7, 176-87
21081844   Curated Info

49

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

50

Hutz JE, Manning WA, Province MA, McLeod HL (2011) Genomewide analysis of inherited variation associated with phosphorylation of PI3K/AKT/mTOR signaling proteins. PLoS One 6, e24873
21949775   Curated Info

51

Yang S, Xiao X, Meng X, Leslie KK (2011) A mechanism for synergy with combined mTOR and PI3 kinase inhibitors. PLoS One 6, e26343
22039466   Curated Info

52

Zhou J (2010) CST Curation Set: 10712; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-PLK Binding Motif (ST*P) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (ST*P) Immunoaffinity Beads Cat#: 5756
Curated Info

53

Tao Z, et al. (2010) Steady-state kinetic and inhibition studies of the mammalian target of rapamycin (mTOR) kinase domain and mTOR complexes. Biochemistry 49, 8488-98
20804212   Curated Info

54

Moritz A (2010) CST Curation Set: 10603; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

55

Moritz A (2010) CST Curation Set: 10611; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

56

Moritz A (2010) CST Curation Set: 10617; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

57

Moritz A (2010) CST Curation Set: 10606; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

58

Moritz A (2010) CST Curation Set: 10616; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

59

Moritz A (2010) CST Curation Set: 10602; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

60

Moritz A (2010) CST Curation Set: 10609; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

61

Moritz A (2010) CST Curation Set: 10604; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

62

Moritz A (2010) CST Curation Set: 10607; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

63

Moritz A (2010) CST Curation Set: 10610; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

64

Moritz A (2010) CST Curation Set: 10613; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

65

Moritz A (2010) CST Curation Set: 10605; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

66

Moritz A (2010) CST Curation Set: 10608; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

67

Moritz A (2010) CST Curation Set: 10612; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

68

Moritz A (2010) CST Curation Set: 10601; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

69

Moritz A (2010) CST Curation Set: 10599; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

70

Moritz A (2010) CST Curation Set: 10597; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

71

Moritz A (2010) CST Curation Set: 10594; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

72

Moritz A (2010) CST Curation Set: 10598; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/Su11274; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

73

Moritz A (2010) CST Curation Set: 10600; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

74

Moritz A (2010) CST Curation Set: 10595; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/Su11274; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

75

Moritz A (2010) CST Curation Set: 10596; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

76

Moritz A (2010) CST Curation Set: 10233; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

77

Moritz A (2010) CST Curation Set: 10238; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

78

Moritz A (2010) CST Curation Set: 10235; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

79

Moritz A (2010) CST Curation Set: 10240; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

80

Moritz A (2010) CST Curation Set: 10232; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

81

Moritz A (2010) CST Curation Set: 10237; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

82

Moritz A (2010) CST Curation Set: 10234; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

83

Moritz A (2010) CST Curation Set: 10241; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

84

Moritz A (2010) CST Curation Set: 10239; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

85

Moritz A (2010) CST Curation Set: 10242; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

86

Moritz A (2010) CST Curation Set: 10236; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

87

Moritz A (2010) CST Curation Set: 10231; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

88

Carayol N, et al. (2010) Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci U S A 107, 12469-74
20616057   Curated Info

89

Moritz A (2010) CST Curation Set: 9985; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

90

Moritz A (2010) CST Curation Set: 9984; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

91

Moritz A (2010) CST Curation Set: 10021; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

92

Moritz A (2010) CST Curation Set: 10020; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

93

Moritz A (2010) CST Curation Set: 9983; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

94

Moritz A (2010) CST Curation Set: 9986; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

95

Moritz A (2010) CST Curation Set: 10022; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

96

Moritz A (2010) CST Curation Set: 9980; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

97

Moritz A (2010) CST Curation Set: 10023; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

98

Moritz A (2010) CST Curation Set: 9987; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

99

Koren I, Reem E, Kimchi A (2010) DAP1, a novel substrate of mTOR, negatively regulates autophagy. Curr Biol 20, 1093-8
20537536   Curated Info

100

Moritz A (2010) CST Curation Set: 9924; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

101

Chen CC, et al. (2010) FoxOs inhibit mTORC1 and activate Akt by inducing the expression of Sestrin3 and Rictor. Dev Cell 18, 592-604
20412774   Curated Info

102

Mallon R, et al. (2010) Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor. Mol Cancer Ther 9, 976-84
20371716   Curated Info

103

Moritz A (2010) CST Curation Set: 9374; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

104

Moritz A (2010) CST Curation Set: 9373; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

105

Soliman GA, et al. (2010) mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J Biol Chem 285, 7866-79
20022946   Curated Info

106

Moritz A (2010) CST Curation Set: 9279; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO &'||' Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

107

Moritz A (2010) CST Curation Set: 9234; Year: 2010; Biosample/Treatment: cell line, MKN-45/calyculin_A & pervanadate; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

108

Moritz A (2010) CST Curation Set: 9240; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

109

Moritz A (2010) CST Curation Set: 9237; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

110

Moritz A (2010) CST Curation Set: 9243; Year: 2010; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

111

Moritz A (2010) CST Curation Set: 9245; Year: 2010; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

112

Moritz A (2010) CST Curation Set: 9239; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

113

Moritz A (2010) CST Curation Set: 9242; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

114

Moritz A (2010) CST Curation Set: 8837; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

115

Chresta CM, et al. (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 70, 288-98
20028854   Curated Info

116

Chen L, Giorgianni F, Beranova-Giorgianni S (2010) Characterization of the phosphoproteome in LNCaP prostate cancer cells by in-gel isoelectric focusing and tandem mass spectrometry. J Proteome Res 9, 174-8
20044836   Curated Info

117

Possemato A (2009) CST Curation Set: 8413; Year: 2009; Biosample/Treatment: cell line, KATO III/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

118

Kjellerup RB, Iversen L, Kragballe K, Johansen C (2009) The expression and phosphorylation of eukaryotic initiation factor 4E are increased in lesional psoriatic skin. Br J Dermatol 161, 1059-66
19663871   Curated Info

119

Van Hoof D, et al. (2009) Phosphorylation dynamics during early differentiation of human embryonic stem cells. Cell Stem Cell 5, 214-26
19664995   Curated Info

120

Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501
19413330   Curated Info

121

Wang L, Lawrence JC, Sturgill TW, Harris TE (2009) Mammalian Target of Rapamycin Complex 1 (mTORC1) Activity Is Associated with Phosphorylation of Raptor by mTOR. J Biol Chem 284, 14693-7
19346248   Curated Info

122

Old WM, et al. (2009) Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell 34, 115-31
19362540   Curated Info

123

Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8
19276368   Curated Info

124

Rose AJ, et al. (2009) Skeletal muscle eEF2 and 4EBP1 phosphorylation during endurance exercise is dependent on intensity and muscle fiber type. Am J Physiol Regul Integr Comp Physiol 296, R326-33
19036825   Curated Info

125

Joughin BA, et al. (2009) An integrated comparative phosphoproteomic and bioinformatic approach reveals a novel class of MPM-2 motifs upregulated in EGFRvIII-expressing glioblastoma cells. Mol Biosyst 5, 59-67
19081932   Curated Info

126

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

127

Zhong D, et al. (2008) LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins. Cancer Res 68, 7270-7
18794113   Curated Info

128

Greenhaff PL, et al. (2008) Disassociation between the effects of amino acids and insulin on signaling, ubiquitin ligases, and protein turnover in human muscle. Am J Physiol Endocrinol Metab 295, E595-604
18577697   Curated Info

129

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

130

Stokes M (2008) CST Curation Set: 4605; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

131

Stokes M (2008) CST Curation Set: 4392; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

132

Fonseca BD, Lee VH, Proud CG (2008) The binding of PRAS40 to 14-3-3 proteins is not required for activation of mTORC1 signalling by phorbol esters/ERK. Biochem J 411, 141-9
18215133   Curated Info

133

Cantin GT, et al. (2008) Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis. J Proteome Res 7, 1346-51
18220336   Curated Info

134

Stokes M (2008) CST Curation Set: 3882; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

135

Jindra PT, Jin YP, Rozengurt E, Reed EF (2008) HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol 180, 2357-66
18250445   Curated Info

136

Fuchs BC, Finger RE, Onan MC, Bode BP (2007) ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells. Am J Physiol Cell Physiol 293, C55-63
17329400   Curated Info

137

Sturrock A, et al. (2007) Nox4 mediates TGF-beta1-induced retinoblastoma protein phosphorylation, proliferation, and hypertrophy in human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 292, L1543-55
17369289   Curated Info

138

Sancak Y, et al. (2007) PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 25, 903-15
17386266   Curated Info

139

Gan B, Yoo Y, Guan JL (2006) Association of focal adhesion kinase with tuberous sclerosis complex 2 in the regulation of s6 kinase activation and cell growth. J Biol Chem 281, 37321-9
17043358   Curated Info

140

Yoon P, et al. (2006) Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells. Mol Cancer Ther 5, 2815-23
17121928   Curated Info

141

Dreyer HC, et al. (2006) Resistance exercise increases AMPK activity and reduces 4E-BP1 phosphorylation and protein synthesis in human skeletal muscle. J Physiol 576, 613-24
16873412   Curated Info

142

Han S, Khuri FR, Roman J (2006) Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res 66, 315-23
16397245   Curated Info

143

Moritz A (2005) CST Curation Set: 595; Year: 2005; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

144

Moritz A (2005) CST Curation Set: 596; Year: 2005; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

145

Moritz A (2005) CST Curation Set: 597; Year: 2005; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

146

Moritz A (2005) CST Curation Set: 598; Year: 2005; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

147

Lal L, et al. (2005) Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood 105, 1669-77
15471950   Curated Info

148

Lekmine F, et al. (2004) Interferon-gamma engages the p70 S6 kinase to regulate phosphorylation of the 40S S6 ribosomal protein. Exp Cell Res 295, 173-82
15051500   Curated Info

149

Moritz A (2003) CST Curation Set: 213; Year: 2003; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

150

Beugnet A, Wang X, Proud CG (2003) Target of rapamycin (TOR)-signaling and RAIP motifs play distinct roles in the mammalian TOR-dependent phosphorylation of initiation factor 4E-binding protein 1. J Biol Chem 278, 40717-22
12912989   Curated Info

151

Lekmine F, et al. (2003) Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. J Biol Chem 278, 27772-80
12759354   Curated Info

152

Moritz A (2003) CST Curation Set: 22; Year: 2003; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

153

Moritz A (2003) CST Curation Set: 23; Year: 2003; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

154

Goss V (2003) CST Curation Set: 29; Year: 2003; Biosample/Treatment: cell line, Jurkat/nocodazole; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

155

Moritz A (2003) CST Curation Set: 13; Year: 2003; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

156

Moritz A (2003) CST Curation Set: 15; Year: 2003; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

157

Moritz A (2003) CST Curation Set: 16; Year: 2003; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

158

Moritz A (2003) CST Curation Set: 17; Year: 2003; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

159

Moritz A (2003) CST Curation Set: 14; Year: 2003; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

160

Moritz A (2003) CST Curation Set: 7; Year: 2003; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

161

Wang X, et al. (2003) The C terminus of initiation factor 4E-binding protein 1 contains multiple regulatory features that influence its function and phosphorylation. Mol Cell Biol 23, 1546-57
12588975   Curated Info

162

McMahon LP, et al. (2002) The rapamycin-binding domain governs substrate selectivity by the mammalian target of rapamycin. Mol Cell Biol 22, 7428-38
12370290   Curated Info

163

Tee AR, et al. (2002) Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A 99, 13571-6
12271141   Curated Info

164

Herbert TP, Tee AR, Proud CG (2002) The extracellular signal-regulated kinase pathway regulates the phosphorylation of 4E-BP1 at multiple sites. J Biol Chem 277, 11591-6
11799119   Curated Info

165

Gingras AC, et al. (2001) Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 15, 2852-64
11691836   Curated Info

166

Mothe-Satney I, et al. (2000) Mammalian target of rapamycin-dependent phosphorylation of PHAS-I in four (S/T)P sites detected by phospho-specific antibodies. J Biol Chem 275, 33836-43
10942774   Curated Info

167

Gingras AC, et al. (1999) Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev 13, 1422-37
10364159   Curated Info

168

Burnett PE, et al. (1998) RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci U S A 95, 1432-7
9465032   Curated Info